Medical Provider Utilities Vaccination 
Integrated Care News by CFHA
MAY 8, 2025
Vaccine hesitancy is the delay in accepting or refusing vaccination despite the availability of vaccination services. It falls on a spectrum of vaccine attitudes and intentions, from those who recognize the importance of vaccines and accept all vaccines on one end of the spectrum to those who refuse all vaccines.
Minnesota Academy of Family Physicians
JUNE 20, 2025
AAFP Denounces Changes to ACIP and Vaccine Recommendations The Minnesota Academy of Family Physicians (MAFP) stands with the American Academy of Family Physicians (AAFP) in denouncing the recent decisions made by Health and Human Services (HHS) Secretary, Robert F. Kennedy, Jr.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Annals of Family Medicine
NOVEMBER 20, 2024
Context: The human papillomavirus (HPV) vaccine is recommended starting at age 9 to reduce risk of HPV linked squamous cell cancers, yet recent data shows that only 58.6% have been vaccinated by age 17. Secondary acceptance is agreeing to a vaccine subsequent to declining in a previous encounter. Child (e.g.,
Alabama Academy of Family Physicians
FEBRUARY 19, 2025
Running from February 4 to May 15, this session promises to bring substantial changes to medical consent laws, Medicaid coverage, rural hospital funding, taxation on essential goods, and the transparency of healthcare costs. HB 2 – Vaccine Consent What’s in the Bill: Sponsored by Rep.
FDA Law Blog
JUNE 7, 2021
It is noteworthy that this sentence that no clinical benefit has been established was deemed by FDA as unnecessary for Aduhelm to provide additional context beyond that the approval is based on reduction in amyloid beta plaques. be “reasonably likely to predict” ultimate clinical benefit). Yesterday’s approval of Aduhelm helped answer that.
FDA Law Blog
MAY 3, 2022
Outside of regulators (and, if I do say so, in a much more entertaining way), John Oliver has taken on the spon-con topic several times, including a 2021 episode highlighting issues with local news spon-con and “dicey medical claims.”
FDA Law Blog
JUNE 2, 2023
For 10 high-cost single source covered outpatient drugs selected annually by CMS, manufacturers would be required to respond to a so-called “price verification survey” by providing not only clinical and utilization information about the drug, but also costs of production, distribution, research, and marketing; revenue and profit; and ex-U.S.
Expert insights. Personalized for you.
130 
Let's personalize your content